The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate (CAGR) of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research (TMR) (. The report states that high prevalence of Parkinson’s disease, rise in geriatric population across the globe, increase in funding for clinical research and grants, etc. are expected to spur the growth of the Parkinson’s disease therapeutic drugs during the forecast period, i.e. 2017 to 2025. North America and Europe are projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. Europe is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2025, which can be ascribed to the high prevalence and rise in incidence rate of Parkinson’s disease in the developed countries in the region such as Germany, France, the U.K., and Italy, promising product pipeline, and various initiatives undertaken by the government and non-profit organizations to promote awareness regarding the disease. The Parkinson’s disease therapeutics market in Europe is expected to witness the highest CAGR of more than 11.0% from 2017-2025.
High prevalence and rise in incidence rate of Parkinson’s disease to fuel the global market
Parkinson’s disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. The exact cause of Parkinson’s disease is not known. It is largely prevalent among the geriatric population. Classifying by gender, men are one-and-half times more affected by the disease than women. According to the Parkinson’s Foundation based in the U.S., it is estimated that worldwide around 7 to 10 million people are affected by Parkinson’s disease and around 1 million Americans are living with it. However, the exact number of patients suffering from Parkinson’s disease is known due to incompleteness and inconsistency in the prevalent studies and underdiagnosed cases. According to the Global Burden of Disease Study, it is estimated that around 13 million people will be affected by Parkinson’s disease worldwide by the year 2040. China has the world’s largest population affected with Parkinson’s disease, which is an estimated 2.5 million people, and the number is likely to become double by the end of 2030, accounting for half of the world’s population suffering from the disease. The rapidly growing geriatric population, coupled with high prevalence and increasing incidence rate of Parkinson’s disease in the developed countries, is projected to a key driving factor of the Parkinson’s disease therapeutics market during the forecast period.
Levodopa combination drugs to be an attractive product segment
The report offers detailed segmentation of the global Parkinson’s disease therapeutics market based on drug class, route of administration, and distribution channel. Among drug classes, the levodopa combination drugs segment is poised to account for the leading share of the global market during the forecast period from 2017 to 2025. Levodopa combination therapy is considered a highly-effective treatment for the motor symptoms associated with Parkinson’s disease and is commonly recommended by physicians across the globe. Carbidopa and levodopa combination therapy is commonly used for management of motor fluctuations in Parkinson’s disease. The recent approval by the United States FDA and launch of Duopa in 2015 by AbbVie Inc. had significantly promoted levodopa combination drugs in 2016. Also, the anticipated launch of pipeline study of CVT-301 by Acorda Therapeutics, Inc. and ND0612 from Mitsubishi Tanabe by the end of 2019 is estimated to propel the segment’s growth during the forecast period
Oral route of administration, followed by intestinal infusion segment, dominates the market
In terms of route of administration, the oral route is projected to dominate the global Parkinson’s disease therapeutics market during the forecast period and is estimated to expand at a CAGR of more than 7.5% from 2017-2025. More than 70% of the drugs available for treatment of Parkinson’s disease are in the tablet and capsule form. Some of the drugs are orally disintegrated. However, the estimated launch of sublingual film by SUNOVION and inhaled formulation by Acorda Therapeutics, Inc. during the forecast period is likely to gain market exceeding 15% by the end of 2025. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson’s disease are estimated to limit the growth of the oral route of administration segment by the end of 2025.
Retail pharmacy, followed by hospital pharmacy segment, dominates the market
Among distribution channels, the retail pharmacy segment is projected to hold the dominant share of the global Parkinson’s disease therapeutics market during the forecast period and is likely to expand at CAGR of more than 11% from 2017 to 2025. Easy availability of Parkinson’s therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The hospital pharmacy segment is the second leading shareholder of the global Parkinson’s disease therapeutics market. However, the segment is likely to lose its market share by the end of 2025. Intestinal infusion drugs and subcutaneously administered drugs, and certain patented drugs, to an extent, have contributed to the key market share of the hospital pharmacy segment in 2016. The online pharmacy segment is poised to grow at as significant CAGR of more than 12% during the forecast period.
Huge incremental opportunity in Europe
In terms of value, Europe dominated the global Parkinson’s disease therapeutics market in 2016. The region is estimated to gain market share by the end of 2025. The dominance of Europe can be primarily attributed to the high prevalence of Parkinson’s disease in the region, availability of and high adoption of levodopa combination drugs, and high clinical R&D budget to address the unmet needs in Parkinson’s disease. According to the European Parkinson’s Disease Association, around 1.2 million people in European Union are affected with Parkinson’s disease. In Germany, around 260,000 people; in Italy, 150,000 people; and in the U.K., around 120,000 people are affected by the disease. The highest incidence rate of Parkinson’s disease is observed in France with around 36-49 cases per 100,000 people. The Parkinson’s disease therapeutics market in Europe is estimated to grow at the highest CAGR of more than 11% during the forecast period. North America is the second leading market for Parkinson’s disease therapeutics. Rapid growth in the aging population of the U.S., rise in awareness regarding Parkinson’s disease, and new product approvals and launches in the region have contributed to the dominant share of the region. Moreover, high clinical R&D budget by the governments, private players, and non-profit organizations are estimated to fuel the expansion of the Parkinson’s disease therapeutics market in North America during the forecast period. The Parkinson’s disease therapeutics market in Asia Pacific is poised to grow at a moderate rate during the forecast period.
For More Details, Request A PDF Brochure Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26975
Key trend of new product development and launch in the international market is observed among leading players
The report also provides profiles of the leading players operating in the global Parkinson’s disease therapeutics market. AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc. are some of the prominent players in the market having proprietary products and technologies. Most of them are focused on new product development, approvals, and commercialization of novel drugs to gain the first-mover’s advantage and address the unmet needs in the Parkinson’s disease therapeutics market. For instance, In January 2015, AbbVie’s flagship product, DUOPA (Combination Drug of carbidopa and levodopa), received the approval of the United States FDA for the treatment of advanced Parkinson’s disease. Duopa is administered through a unique technology directly into the intestine of the patient through the stoma. It is the first and only kind of product administered through intestinal infusion. In 2016, the ACADIA Pharmaceuticals Inc. launched its antipsychotic drug, Nuplazid, in the U.S. Nuplazid is the first and only drug approved by the United States FDA for the management of hallucination and delusion associated with Parkinson’s disease. Other prominent players operating in the global Parkinson’s disease therapeutics market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.